Akebia Therapeutics Inc. (NASDAQ: AKBA) has announced that it will present vadadustat safety and efficacy data associated with clinical outcomes among anemia patients with chronic kidney disease (CKD) at the virtual American Society of Nephrology Kidney Week 2021 (ASN Kidney Week) taking place between November 4, 2021, and November 7, 2021.
Vadadustat is a potential anemia treatment due to CKD
Vadadustat is an experimental oral hypoxia-inducible factor prolyl hydroxylase inhibitor developed by Akebia. It is a potential first-in-class drug in the United States for treating anemia caused by CKD by mimicking the physiologic effect of altitude in the viability of oxygen. At higher altitudes, the body will respond to low oxygen availability with hypoxia-inducible factors stabilization, which can result in increased red blood cells production leading to enhanced oxygen delivery to tissues.
Vadadustat is currently under review by the US Food and Drug Administration, with a PDUFA date of March 29, 2022. However, the new experimental drug doesn’t have FDA approval or form any regulatory authority apart from Japan’s Ministry of Health Labor and Welfare. In Japan, the drug has been approved to treat anemia caused by CKD in dialysis-dependent and non-dialysis-dependent adult patients.
Akebia to present data of Auryxia during ASN Kidney Week 2021
CEO John Butler said, “We look forward to ASN as an opportunity to continue to share rich data on vadadustat with the nephrology community. We believe these data demonstrate the efficacy and safety profile of vadadustat as a potential oral treatment for patients living with anemia due to chronic kidney disease.”
In addition, Akebia will present Auryxia® (ferric citrate) data, which includes a poster on the study design of a collaborative clinical trial using Auryxia to avoid renal failure in people with advanced CKD. The ASN Kidney Week abstract portal now has all of the accepted vadadustat poster abstracts as well as other Akebia abstracts.
